Clinical program director: Prof. dr. Max van Noesel
Phone
Departmental research and clinical trials program
- Bone tumors lead to drastic changes in the future of children through amputations, prostheses and thus changes in their own body image and physical limitations. In addition, the chances of recovery are insufficient and have not improved (internationally) for many years. Our department has a focus on children with bone tumors The aim is 5-fold: a) molecular analysis of bone tumors, b) Development of novel targets for treatment , c) 3D-imaging-based and fluorescence-guided surgery, d)Development of cellular immunotherapy (e.g. CAR-T) and e) Development of liquid biopsy/blood based diagnostics.
- In neuroblastoma and rhabdomyosarcoma, we focus on the implementation of early diagnostic blood diagnostics ('liquid biopsies') and early detection of minimal disease in the blood or relapsed disease.
- Understand drug sensitivity of tumors by screening the child's own tumor in the laboratory for drug sensitivity ('Drug Screening').
- Development and implementation of immunotherapies. For neuoblastoma in particular, we implemented anti-GD2 antibody therapy in several clinical trials. The next steps in immunotherapy are the development and clinical application of cellular immunotherapy with the patient's own genetically engineered T-immune cells (so called CAR-T cells) targeted against their tumor cells.
“The program has a broad focus on improved diagnostics, development of targeted treatment, reducing treatment related toxicity and improvement of quality of life." Prof. dr. Max van Noesel - Clinical program director
Personal focus
In addition, Max van Noesel's personal focus is on two projects:
- Theranostics - In collaboration with prof. Marnix Lam, Dr Braat, Dr de Keizer, Dr Tolboom, Dr Poot, UMC Utrecht
Tracer development and clinical studies: Development of [211At]- MABG treatment for neuroblastoma , LUDO-N study, a phase 1 [177Lu]Dotatate treatment in children with relapsed neuroblastoma; [68Ga]-SATO -PET study, imaging study in pediatric neural crest tumors with the SSTR-antagonist SATO; [18F]-MFBG imaging study for diagnosis and staging of neuroblastoma tumors; [89Zr]-anti-GD2 PET study for imaging of the GD2 biomarker in neuroblastoma, osteosarcoma and Ewing sarcoma (expected to open within 2 yrs). - Development of clinical studies - In collaboration with the Molenaar-lab.
- Collaboration in trans-Atlantic NANT consortium for early clinical trials in neuroblastoma. In 2025 and 2026 two trials are expected to open: MIGHTY, a platform trial for molecular and immunological data on children in relapsed disease trials and TACTIC, a clinical trial with the combination of chemotherapy and immunotherapy (anti-GD2 plus anti-PDL-1 plus anti-TIGIT).
- International MYKIDS study, a platform trial for molecular diagnosis and development of liquid biopsies and organoids for Non-Rhabdo Soft Tissue Sarcoma (NRSTS) in children.
Key publications
1. Rare pediatric tumors benefit from large clinical trials: The story of undifferentiated embryonal sarcoma of the liver Max M van Noesel Cancer. 2024 May 8. doi: 10.1002/cncr.35327.PMID: 38717946
2. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy Judith Wienke, Lindy L Visser, Waleed M Kholosy, Kaylee M Keller, Marta Barisa, Evon Poon, Sophie Munnings-Tomes, Courtney Himsworth, Elizabeth Calton, Ana Rodriguez, Ronald Bernardi, Femke van den Ham, Sander R van Hooff, Yvette A H Matser, Michelle L Tas, Karin P S Langenberg, Philip Lijnzaad2, Anne L Borst, Elisa Zappa, Francisca J Bergsma, Josephine G M Strijker, Bronte M Verhoeven, Shenglin Mei, Amira Kramdi, Restuadi Restuadi, Alvaro Sanchez-Bernabeu, Annelisa M Cornel, Frank C P Holstege, Juliet C Gray, Godelieve A M Tytgat, Marijn A Scheijde-Vermeulen, Marc H W A Wijnen, Miranda P Dierselhuis, Karin Straathof, Sam Behjati, Wei Wu, Albert J R Heck, Jan Koster, Stefan Nierkens, Isabelle Janoueix-Lerosey, Ronald R de Krijger, Ninib Baryawno, Louis Chesler, John Anderson, Hubert N Caron, Thanasis Margaritis, Max M van Noesel, Jan J Molenaar Cancer Cell. 2024 Feb 12;42(2):283-300.e8. doi: 10.1016/j.ccell.2023.12.008.PMID: 38181797
3. Inflammatory Myofibroblastic Tumor With ROS1 Gene Fusions in Children and Young Adolescents Reineke A. Schoot, Daniel Orbach, Veronique Minard Colin, Rita Alaggio, MD4; Daniela Di Carlo, Nadege Corradini, Federico Mercolini, Giuseppe Maria Milano, Max M. van Noesel, Angelique Rome, Patrizia Dall’Igna, Kristian Pajtler, Monika Sparber-Sauer, Andrea Ferrari, and Michela Casanova. JCO Precis Oncol. 2023 Sep;7:e2300323. doi: 10.1200/PO.23.00323.PMID: 37856763
4. A joint international consensus statement for measuring quality of survival for patients with childhood cancer. van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, Hakkert J, den Hartogh J, Nijenhuis A, van Santen HM, Schouten-van Meeteren AYN, van Tinteren H, Verbruggen LC, Conklin HM, Jacola LM, Webster RT, Partanen M, Kollen WJW, Grootenhuis MA, Pieters R, Kremer LCM; International Childhood Cancer Outcome Project participants. Nat Med. 2023 Jun;29(6):1340-1348. doi: 10.1038/s41591-023-02339-y. Epub 2023 Jun 15.PMID: 37322119
5. [18F]mFBG PET‑CT for detection and localisation of neuroblastoma: a prospective pilot study Samim A, Blom T, Poot AJ, Windhorst AD, Fiocco M, Tolboom N, Braat AJAT, Viol SLM, van Rooij R, van Noesel MM, Lam MGEH, Tytgat GAM, de Keizer B. Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1146-1157. doi: 10.1007/s00259-022-06063-6. Epub 2022 Dec 12.PMID: 36504277
6. Assessment of Cancer Predisposition Syndromes in a National Cohort of Children With a Neoplasm Jette J. Bakhuizen, Saskia M. J. Hopman, Machteld I. Bosscha, Charlotte J. Dommering, Marry M. van den Heuvel-Eibrink, Janna A. Hol, Lennart A. Kester, Marco J. Koudijs, Karin P. S. Langenberg, Jan L. C. Loeffen, Jasper van der Lugt, Annette C. Moll, Max M. van Noesel, Stephanie E. Smetsers, Evelien de Vos-Kerkhof, Johannes H. M. Merks, Roland P. Kuiper, Marjolijn C. J. Jongmans. JAMA Netw Open. 2023 Feb 1;6(2):e2254157. doi: 10.1001/jamanetworkopen.2022.54157.PMID: 36735256
7. Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma Lak NSM, van Zogchel LMJ, Zappeij-Kannegieter L, Javadi A, van Paemel R, Vandeputte C, De Preter K, De Wilde B, Chicard M, Iddir Y, Schleiermacher G, Ruhen O, Shipley J, Fiocco M, Merks JHM, van Noesel MM, van der Schoot CE, Tytgat GAM, Stutterheim J. JCO Precis Oncol. 2023 Jan;7:e2200113. doi: 10.1200/PO.22.00113.PMID: 36652664
8. Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER' Karin P S Langenberg, Michael T Meister, Jette J Bakhuizen, Judith M Boer, Natasha K A van Eijkelenburg, Esther Hulleman, Uri Ilan, Eleonora J Looze, Miranda P Dierselhuis, Jasper van der Lugt, Willemijn Breunis, Linda G Schild, Kimberley Ober, Sander R van Hooff, Marijn A Scheijde-Vermeulen, Laura S Hiemcke-Jiwa, Uta E Flucke, Mariette E G Kranendonk, Pieter Wesseling 6, Edwin Sonneveld, Simone Punt, Arjan Boltjes, Freerk van Dijk, Eugene T P Verwiel, Richard Volckmann, Jayne Y Hehir-Kwa, Lennart A Kester, Marco M J Koudijs, Esme Waanders, Frank C P Holstege, H Josef Vormoor, Eelco W Hoving, Max M van Noesel, Rob Pieters, Marcel Kool, Miriam Stumpf, Mirjam Blattner-Johnson, Gnana P Balasubramanian, Cornelis M Van Tilburg, Barbara C Jones, David T W Jones, Olaf Witt, Stefan M Pfister, Marjolijn C J Jongmans, Roland P Kuiper, Ronald R de Krijger, Marc H W Wijnen, Monique L den Boer, C Michel Zwaan, Patrick Kemmeren, Jan Koster, Bastiaan B J Tops, Bianca F Goemans, Jan J Molenaar. Eur J Cancer. 2022 Nov;175:311-325. doi: 10.1016/j.ejca.2022.09.001. Epub 2022 Sep 29.PMID: 36182817
9. Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas: Standard of Care and Treatment Recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) Andrea Ferrari, Bernadette Brennan, Michela Casanova, Nadege Corradini, Pablo Berlanga, Reineke A Schoot, Gema L Ramirez-Villar, Akmal Safwat, Gabriela Guillen Burrieza, Patrizia Dall'Igna, Rita Alaggio, Lisa Lyngsie Hjalgrim, Susanne Andrea Gatz, Daniel Orbach, Max M van Noesel Cancer Manag Res. 2022 Sep 23;14:2885-2902. doi: 10.2147/CMAR.S368381. eCollection 2022.PMID: 36176694
2. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy Judith Wienke, Lindy L Visser, Waleed M Kholosy, Kaylee M Keller, Marta Barisa, Evon Poon, Sophie Munnings-Tomes, Courtney Himsworth, Elizabeth Calton, Ana Rodriguez, Ronald Bernardi, Femke van den Ham, Sander R van Hooff, Yvette A H Matser, Michelle L Tas, Karin P S Langenberg, Philip Lijnzaad2, Anne L Borst, Elisa Zappa, Francisca J Bergsma, Josephine G M Strijker, Bronte M Verhoeven, Shenglin Mei, Amira Kramdi, Restuadi Restuadi, Alvaro Sanchez-Bernabeu, Annelisa M Cornel, Frank C P Holstege, Juliet C Gray, Godelieve A M Tytgat, Marijn A Scheijde-Vermeulen, Marc H W A Wijnen, Miranda P Dierselhuis, Karin Straathof, Sam Behjati, Wei Wu, Albert J R Heck, Jan Koster, Stefan Nierkens, Isabelle Janoueix-Lerosey, Ronald R de Krijger, Ninib Baryawno, Louis Chesler, John Anderson, Hubert N Caron, Thanasis Margaritis, Max M van Noesel, Jan J Molenaar Cancer Cell. 2024 Feb 12;42(2):283-300.e8. doi: 10.1016/j.ccell.2023.12.008.PMID: 38181797
3. Inflammatory Myofibroblastic Tumor With ROS1 Gene Fusions in Children and Young Adolescents Reineke A. Schoot, Daniel Orbach, Veronique Minard Colin, Rita Alaggio, MD4; Daniela Di Carlo, Nadege Corradini, Federico Mercolini, Giuseppe Maria Milano, Max M. van Noesel, Angelique Rome, Patrizia Dall’Igna, Kristian Pajtler, Monika Sparber-Sauer, Andrea Ferrari, and Michela Casanova. JCO Precis Oncol. 2023 Sep;7:e2300323. doi: 10.1200/PO.23.00323.PMID: 37856763
4. A joint international consensus statement for measuring quality of survival for patients with childhood cancer. van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, Hakkert J, den Hartogh J, Nijenhuis A, van Santen HM, Schouten-van Meeteren AYN, van Tinteren H, Verbruggen LC, Conklin HM, Jacola LM, Webster RT, Partanen M, Kollen WJW, Grootenhuis MA, Pieters R, Kremer LCM; International Childhood Cancer Outcome Project participants. Nat Med. 2023 Jun;29(6):1340-1348. doi: 10.1038/s41591-023-02339-y. Epub 2023 Jun 15.PMID: 37322119
5. [18F]mFBG PET‑CT for detection and localisation of neuroblastoma: a prospective pilot study Samim A, Blom T, Poot AJ, Windhorst AD, Fiocco M, Tolboom N, Braat AJAT, Viol SLM, van Rooij R, van Noesel MM, Lam MGEH, Tytgat GAM, de Keizer B. Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1146-1157. doi: 10.1007/s00259-022-06063-6. Epub 2022 Dec 12.PMID: 36504277
6. Assessment of Cancer Predisposition Syndromes in a National Cohort of Children With a Neoplasm Jette J. Bakhuizen, Saskia M. J. Hopman, Machteld I. Bosscha, Charlotte J. Dommering, Marry M. van den Heuvel-Eibrink, Janna A. Hol, Lennart A. Kester, Marco J. Koudijs, Karin P. S. Langenberg, Jan L. C. Loeffen, Jasper van der Lugt, Annette C. Moll, Max M. van Noesel, Stephanie E. Smetsers, Evelien de Vos-Kerkhof, Johannes H. M. Merks, Roland P. Kuiper, Marjolijn C. J. Jongmans. JAMA Netw Open. 2023 Feb 1;6(2):e2254157. doi: 10.1001/jamanetworkopen.2022.54157.PMID: 36735256
7. Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma Lak NSM, van Zogchel LMJ, Zappeij-Kannegieter L, Javadi A, van Paemel R, Vandeputte C, De Preter K, De Wilde B, Chicard M, Iddir Y, Schleiermacher G, Ruhen O, Shipley J, Fiocco M, Merks JHM, van Noesel MM, van der Schoot CE, Tytgat GAM, Stutterheim J. JCO Precis Oncol. 2023 Jan;7:e2200113. doi: 10.1200/PO.22.00113.PMID: 36652664
8. Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER' Karin P S Langenberg, Michael T Meister, Jette J Bakhuizen, Judith M Boer, Natasha K A van Eijkelenburg, Esther Hulleman, Uri Ilan, Eleonora J Looze, Miranda P Dierselhuis, Jasper van der Lugt, Willemijn Breunis, Linda G Schild, Kimberley Ober, Sander R van Hooff, Marijn A Scheijde-Vermeulen, Laura S Hiemcke-Jiwa, Uta E Flucke, Mariette E G Kranendonk, Pieter Wesseling 6, Edwin Sonneveld, Simone Punt, Arjan Boltjes, Freerk van Dijk, Eugene T P Verwiel, Richard Volckmann, Jayne Y Hehir-Kwa, Lennart A Kester, Marco M J Koudijs, Esme Waanders, Frank C P Holstege, H Josef Vormoor, Eelco W Hoving, Max M van Noesel, Rob Pieters, Marcel Kool, Miriam Stumpf, Mirjam Blattner-Johnson, Gnana P Balasubramanian, Cornelis M Van Tilburg, Barbara C Jones, David T W Jones, Olaf Witt, Stefan M Pfister, Marjolijn C J Jongmans, Roland P Kuiper, Ronald R de Krijger, Marc H W Wijnen, Monique L den Boer, C Michel Zwaan, Patrick Kemmeren, Jan Koster, Bastiaan B J Tops, Bianca F Goemans, Jan J Molenaar. Eur J Cancer. 2022 Nov;175:311-325. doi: 10.1016/j.ejca.2022.09.001. Epub 2022 Sep 29.PMID: 36182817
9. Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas: Standard of Care and Treatment Recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) Andrea Ferrari, Bernadette Brennan, Michela Casanova, Nadege Corradini, Pablo Berlanga, Reineke A Schoot, Gema L Ramirez-Villar, Akmal Safwat, Gabriela Guillen Burrieza, Patrizia Dall'Igna, Rita Alaggio, Lisa Lyngsie Hjalgrim, Susanne Andrea Gatz, Daniel Orbach, Max M van Noesel Cancer Manag Res. 2022 Sep 23;14:2885-2902. doi: 10.2147/CMAR.S368381. eCollection 2022.PMID: 36176694
Grants and awards
2024 Solving Kids Cancer/ACTION consortium. Molecular and lmmunologic guided high risk neuroblastoma TherapY(MIGHTY). vNoesel en Park
2023 Stichting Villa Joep/Maarten vd Weijden Foundation/St Villa Joep
2023 KIKA grant 459 ‘Liquid biopsies in pediatric soft tissue sarcoma’. Co-Pi
2022 KIKA Grant 462 “Developing nuclear nanobody-based theranostics for high- risk pediatric sarcomas”. vNoesel en Janda.
2021 KiTZ-Máxima Grant: Development and implementation of a personalized drug sensitivity profiling pipeline as stratification method for pediatric patients with solid and central nervous system tumors. PI’s: M. van Noesel and I Oehme. 2022 Butterfly Initiative, in association with Villa Joep- “Diagnostic radiopharmaceuticals for neuroblastoma tumors”- vNoesel, Poot, Tolboom
2021 KiTZ-Máxima Grant: Development and implementation of a personalized drug sensitivity profiling pipeline as stratification method for pediatric patients with solid and central nervous system tumors. vNoesel en Oehme.
2019 UMCU-PMC research program-Nuclear Medicine and Molecular Imaging in pediatric tumors. vNoesel en Lam.
2023 Stichting Villa Joep/Maarten vd Weijden Foundation/St Villa Joep
2023 KIKA grant 459 ‘Liquid biopsies in pediatric soft tissue sarcoma’. Co-Pi
2022 KIKA Grant 462 “Developing nuclear nanobody-based theranostics for high- risk pediatric sarcomas”. vNoesel en Janda.
2021 KiTZ-Máxima Grant: Development and implementation of a personalized drug sensitivity profiling pipeline as stratification method for pediatric patients with solid and central nervous system tumors. PI’s: M. van Noesel and I Oehme. 2022 Butterfly Initiative, in association with Villa Joep- “Diagnostic radiopharmaceuticals for neuroblastoma tumors”- vNoesel, Poot, Tolboom
2021 KiTZ-Máxima Grant: Development and implementation of a personalized drug sensitivity profiling pipeline as stratification method for pediatric patients with solid and central nervous system tumors. vNoesel en Oehme.
2019 UMCU-PMC research program-Nuclear Medicine and Molecular Imaging in pediatric tumors. vNoesel en Lam.
